0
Deep & Emerging Tech·June 22, 2026·1 min read

How Eli Lilly Became a $1 Trillion Company

Share

Lilly’s path to a $1T valuation on the back of Mounjaro and Zepbound is a case study in what happens when a single therapeutic category becomes a macro asset class. If you’re in health or adjacent data/infra, assume GLP-1 economics will shape payer behavior, employer benefits, and patient expectations — and build offerings that either ride or hedge that concentration.